Injectable Drug Delivery Market by Device Type, Usability, Therapeutic Application, End-user

Description

List of Tables

[190 Pages Report] The Injectable Drug Delivery Market size was estimated at USD 972.25 billion in 2023 and expected to reach USD 1,042.06 billion in 2024, at a CAGR 7.58% to reach USD 1,621.71 billion by 2030.

The injectable drug delivery market includes technologies, devices, and formulations used for administering drugs into the body through a needle or similar device. Technological innovations in needle technology, such as the development of needle-free injection systems, contribute to market growth. The rise in conditions such as diabetes and cancer necessitates robust drug delivery systems, including injectables. Faster approval processes for new drugs and devices help drive the adoption of advanced injectable technologies. However, maintaining the integrity of drugs through specialized storage and handling needs adds complexity, limiting the market scope. Stringent global regulations may delay product launches, challenging market growth. Moreover, the development of smart injection devices that adjust doses based on real-time patient data can generate the potential for personalized treatment. Ongoing research into biodegradable implants reduces the need for frequent injections, creating significant potential for market expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 972.25 billion
Estimated Year [2024]	USD 1,042.06 billion
Forecast Year [2030]	USD 1,621.71 billion
CAGR (%)	7.58%

Regional Insights

The Americas region has significance in the global injectable drug delivery market due to its advanced healthcare infrastructure, strong emphasis on research and development, and significant healthcare spending. The focus in the United States and Canada is increasingly on biologics and biosimilars owing to their efficacy in treating chronic diseases such as diabetes and cancer. Recent patents in the region have highlighted innovations in needle-free injections and sustained-release formulations, enhancing patient compliance. Countries within the EU exhibit a strong pipeline for biologics and advanced drug delivery devices backed by rigorous regulatory standards. Recent EU investments focus on improving drug formulations and reducing the discomfort associated with injections. The Middle East and Africa region experiences varying growth levels driven by disparities in healthcare infrastructure. The Middle East region benefits from the luxury healthcare facilities in countries such as the UAE and Saudi Arabia that focus on adopting advanced drug delivery systems, including smart injectables. Africa is a developing region in this sector, showing potential due to increasing healthcare investments and rising awareness about advanced therapeutic measures. In the Asia-Pacific region, China is rapidly advancing in the injectable drug delivery field, buoyed by large-scale investments in healthcare and pharmaceutical R&D. Japan has introduced several reforms to expedite the approval process for new drugs, including injectables. India's injectable drug delivery market is burgeoning, facilitated by the large generic drugs industry and a growing focus on chronic disease management.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Injectable Drug Delivery Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Technological advancements in needle technology
- Increasing prevalence of chronic diseases
- Significant rise in elderly population worldwide

Market Restraints
- High development costs of injectable drug delivery solutions

Market Opportunities
- Development of smart injection devices
- Increasing demand for self-administration devices

Market Challenges
- Low patient compliance of needles and lack of training in using injectable devices

Market Segmentation Analysis
- Device Type: Increasing preference for self-injection devices due to ease of use
- End-user: Exploring applications in home care settings due to safety and portability

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Injectable Drug Delivery Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Injectable Drug Delivery Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Stevanato Group Launches Vertiva, An Innovative On-Body Drug Delivery System for Enhanced Patient Care and Sustainability

Stevanato Group, S.p.A. has launched Vertiva, its advanced On-Body Delivery System (OBDS), designed to revolutionize patient medication administration by supporting both basal and bolus injections. Engineered to cater to a diverse array of subcutaneous therapies, Vertiva features a novel, two-part design comprising a single-use, pre-filled 3mL ISO cartridge pod and a reusable multi-use controller. [Published On: 2023-12-06]

Altaviz Introduces AltaVISC, A Revolutionary Auto-injector Platform Enhancing Drug Delivery Efficiency

Altaviz, a medical device manufacturer, has launched AltaVISC, a cutting-edge auto-injector platform designed to effectively administer a diverse range of drug therapies. Developed in collaboration with affiliate company Picocy, this innovative platform incorporates Pico-Cylinder technology to manage the delivery of both high-volume and viscous medications. AltaVISC stands out with its ability to handle shear-sensitive molecules and viscous biologics, maintaining a consistent form factor while offering a wide pressure range for precise control under various environmental conditions. [Published On: 2023-10-16]

Launch of UDENYCA Autoinjector Enhances Patient Accessibility and Administration Efficiency

Coherus BioSciences, Inc. has announced the commercial availability of the UDENYCA autoinjector in the United States, offering a new, user-friendly option for administering the pegfilgrastim biosimilar. Designed for use either in medical facilities or at home, the UDENYCA(R) autoinjector simplifies the injection process, delivering medication in under ten seconds and potentially reducing the occurrence of febrile neutropenia following chemotherapy. The introduction of this autoinjector aligns with Coherus's strategic goal to diversify their product offerings, ensuring they meet broad market needs. [Published On: 2023-05-22]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Injectable Drug Delivery Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drug Delivery Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma by Halozyme Therapeutics, Becton, Dickinson and Company, Eli Lilly and Company, Emperra GmbH, Enable Injections LLC, F. Hoffman - La Roche Ltd., Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PlC, Novo Nordisk A/S, Pfizer, Inc., Ravimed Sp. z o.o., Recipharm AB, Sanofi S.A., SiO2 Medical Products, Stevanato Group, Tandem Diabetes Care, West Pharmaceutical Services, Inc., and Wilhelm Haselmeier GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Injectable Drug Delivery Market to forecast the revenues and analyze trends in each of the following sub-markets:

Device Type
- Conventional Injection Devices
- Self-injection Devices
  - Autoinjectors
  - Needle-free Injectors
  - Pen Injectors
  - Wearable Injectors
Usability
- Disposable
- Reusable

Therapeutic Application
- Autoimmune Diseases
- Cancer
- Chronic Diseases
- Hormonal Therapies
- Infectious Diseases

End-user
- Home Care Settings
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-CB04E0565350

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Technological advancements in needle technology
  - 5.1.1.2. Increasing prevalence of chronic diseases
  - 5.1.1.3. Significant rise in elderly population worldwide
- 5.1.2. Restraints
  - 5.1.2.1. High development costs of injectable drug delivery solutions
- 5.1.3. Opportunities
  - 5.1.3.1. Development of smart injection devices
  - 5.1.3.2. Increasing demand for self-administration devices
- 5.1.4. Challenges
  - 5.1.4.1. Low patient compliance of needles and lack of training in using injectable devices
5.2. Market Segmentation Analysis
- 5.2.1. Device Type: Increasing preference for self-injection devices due to ease of use
- 5.2.2. End-user: Exploring applications in home care settings due to safety and portability
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Injectable Drug Delivery Market, by Device Type

6.1. Introduction
6.2. Conventional Injection Devices
6.3. Self-injection Devices

7. Injectable Drug Delivery Market, by Usability

7.1. Introduction
7.2. Disposable
7.3. Reusable

8. Injectable Drug Delivery Market, by Therapeutic Application

8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Chronic Diseases
8.5. Hormonal Therapies
8.6. Infectious Diseases

9. Injectable Drug Delivery Market, by End-user

9.1. Introduction
9.2. Home Care Settings
9.3. Hospitals & Clinics

10. Americas Injectable Drug Delivery Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Injectable Drug Delivery Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drug Delivery Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Stevanato Group Launches Vertiva, An Innovative On-Body Drug Delivery System for Enhanced Patient Care and Sustainability
- 13.3.2. Altaviz Introduces AltaVISC, A Revolutionary Auto-injector Platform Enhancing Drug Delivery Efficiency
- 13.3.3. Launch of UDENYCA Autoinjector Enhances Patient Accessibility and Administration Efficiency
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio